ArticleOncoscience2017
Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade.
Article in Oncoscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The promise of immunotherapy for central nervous system tumours.Nature reviews. Immunology · 2026Review
- Promoting the therapeutic potential of interleukin-7 (IL-7) by expression in viral vectors.Cancer gene therapy · 2025Review
- The Potential of Oncolytic Virotherapy in the Treatment of Head and Neck Cancer: A Comprehensive Review.International journal of molecular sciences · 2024Review
- Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.Journal for immunotherapy of cancer · 2024Article
- Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy.Human gene therapy · 2023Review
- Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma.Cancer innovation · 2023Review
- Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12.Communications medicine · 2023Article
- Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.Frontiers in immunology · 2022Review
- Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas.Nature communications · 2021Article
- Review
- Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.Journal for immunotherapy of cancer · 2020Article
- Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.Cells · 2020Review
- Glioblastoma Immune Landscape and the Potential of New Immunotherapies.Frontiers in immunology · 2020Review
- Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.Immunotherapy · 2018Article
- Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.